Vilanterol (trifenatate)

Vilanterol (trifenatate)

• CAS Number: 503070-58-4
• UNSPSC Description: Vilanterol trifenatate (GW642444 trifenatate) is a long-acting β2-adrenoceptor (β2-AR) agonist with inherent 24-hour activity. The pEC50s for β2-AR, β1-AR and β3-AR are 10.37, 6.98 and 7.36, respectively.
• Target Antigen: Adrenergic Receptor
• Type: Reference compound
• Related Pathways: GPCR/G Protein;Neuronal Signaling
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology; Endocrinology; Cancer
• Assay Protocol: https://www.medchemexpress.com/Vilanterol-trifenatate.html
• Solubility: DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: OC1=CC=C([C@@H](O)CNCCCCCCOCCOCC2=C(Cl)C=CC=C2Cl)C=C1CO.O=C(O)C(C3=CC=CC=C3)(C4=CC=CC=C4)C5=CC=CC=C5
• Molecular Weight: 774.77
• References & Citations: [1]Slack RJ, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013 Jan;344(1):218-30|[2]Kempsford R, et al. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013 Apr;26(2):256-|[3]Harrell AW, et al. Metabolism and disposition of Vilanterol, a long-acting β(2)-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013 Jan;41(1):89-100.Centre for Neuroscience. University of Alberta. 2016.|Mental Health and Neuroscience Institute. University of Alberta. 2016 Sep.|Eur J Pharmacol. 2017 Oct 5;812:147-154.|J Neuroimmunol. 2019 Jul 15;332:37-48.|J Pharmaceut Biomed. 2020, 113870.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched